New diabetes clinical trial: FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Published on: June 06, 2019 at 07:00PM
Condition:   Type 1 Diabetes Mellitus
Interventions:   Drug: Fiasp®;   Drug: Novolog®;   Device: 670G hybrid closed loop continuous subcutaneous insulin infusion system
Sponsor:   Texas Diabetes & Endocrinology, P.A.
Recruiting